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1. INTRODUCTION AND AIMS 
One of the greatest challenges to overcome in drug development is the efficient 
translocation of protein-sized drugs into cells, because the mammalian cell membrane acts as a 
major obstacle to these hydrophilic large molecules, which could otherwise be highly specific, 
efficient, and tolerable pharmaceuticals. Internalization of these molecules can be achieved by 
clathrin-independent endocytosis (such as lipid-raft mediated/caveolar endocytosis), and this 
pathway is exploited by endogenous proteins, bacterial toxins (cholera and tetanus), and viruses 
(murine polyomavirus and echovirus 1), because this pathway tends to fuse with lysosomes 
only after a very long endosomal retention time, if at all. This endocytic mechanism is an 
attractive target to deliver functional proteins without degradation, and the leaky endosomes 
forming in the process allow direct escape for the molecules before moving to other cellular 
locations. The surface of these lipid rafts and caveolar pits are composed of various 
glycosphingolipids, especially of mono-, di-, and trisialotetrahexosylgangliosides (GM1, 
GD1a, GT1b), which are the major receptors for the natural cargoes. Binding and clustering the 
gangliosides induce an endocytic mechanism, where lysosomal fusion is negligible, allowing 
the proteins to reach the cytosol or undergo transcytosis. Many delivery systems fail to avoid 
lysosomal entrapment, or the molecule responsible for the internalization is required to be used 
at therapeutically irrelevant, high concentrations. Interpreting the glycan code by studying how 
gangliosides trigger endocytosis could be the key to solve these problems. Interest in binding 
gangliosides has already arisen; however, high-affinity molecular recognition is still a great 
challenge. The specific targeting of ganglioside GM1 is especially sought, because this 
ganglioside, while normally being expressed in many mammalian cell types, is highly abundant 
in cancerous cells. Therapeutic protein levels in the extracellular fluid yield 100–500 nM; 
therefore, a high-affinity interaction is needed to create a cell membrane enrichment that 
facilitates sufficient material flux in clinical applications. 
Our main goal was to achieve nanomolar delivery of large proteins (up to the size of antibodies) 
via lipid raft-mediated endocytosis. We aimed to use a non-toxic peptide tag to mimic the 
ganglioside-mediated internalization of endogenous and exogenous proteins; therefore, we set 
out to find a minimal motif that can bind ganglioside GM1 with high affinity and specificity. 
By focusing on a structurally well-defined receptor and conducting a thorough biophysical 
characterization of the interaction, we aimed to open a way to structure-based design, which is 
rare in protein delivery approaches. We set out to investigate the ability of the characterized 
peptidic tag to deliver large proteins into the cells, while rigorously monitoring its toxicity, 
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mechanism of entry, and the tendency to fuse with lysosomes. Using a medicinal chemistry 
approach, we set out to establish a structure–activity relationship, to gain insight into the 
binding mechanism, and to improve the enzymatic stability while retaining high affinity. 
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2. METHODS 
Isothermal titration calorimetry (ITC) 
Isothermal titration calorimetric experiments were performed with the synthesized 
peptides, peptide-conjugates and their target gangliosides (GM1, asialo GM1, GM3) using a 
MicroCal VP-ITC calorimeter. Ganglioside:dodecylphosphocholine 1:5 bicelles were titrated 
to peptides and their conjugates at pH 7.2, 35 °C using 15 M ganglioside concentration. 
Fluorescence activated cell sorting (FACS) 
The internalization of peptides and peptide complexes was determined by flow cytometric 
analysis. Cells were incubated with peptides or peptide complexes at 37 °C for various times. 
The cells were then washed and harvested from the plates with trypsin-EDTA. Trypan blue and 
propidium iodide were added to the cells in phosphate buffered saline immediately before the 
cells were subjected to flow cytometric analysis (FACSCalibur flow cytometer, BD 
Biosciences). The data were evaluated using FlowJo™ software (FlowJo, LLC). For the in vitro 
competition assay, Jurkat cells were treated with peptide alone or with different concentrations  
of galectin-1. For the endocytosis inhibition experiments, HeLa cells were preincubated at 37 
°C with methyl--cyclodextrin (MBCD), wortmannin, or chlorpromazine. The cells were then 
incubated with peptide complexes at 37 °C for 60 min, treated with trypan blue, and subjected 
to flow cytometric analysis as described above. 
Confocal laser scanning microscopy (CLSM) 
The cells were incubated with the studied complexes at different concentrations for 
different incubation times at 37°C. The cells then were washed with PBS; when antibody-
complexes were used, they were also washed with -lactose and the biotinylated peptide-
NeutrAvidin complex without the primary and secondary antibody to remove surface-bound 
complexes. The cells were stained with Hoechst 33342 for 30 min at 37°C. In some 
experiments, after Hoechst staining, the cells were labeled with LysoTracker Red at 37°C 
according to the manufacturer’s instructions. For the cholera toxin colocalization experiments, 
cells were co-incubated with FITC-labeled CTX-B subunit. For the structural test of the 
antibody complex, cells were treated with the complex, then the cells were fixed with 
paraformaldehyde at room temperature, permeabilized saponine and then cells were stained 
with Atto488-conjugated galectin-1 for 30 minutes at room temperature. For the IgG complex 
measurements, cell membranes were visualized with FITC-labeled WGA lectin after incubation 
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with the complex. FITC-NeutrAvidin complexes were treated with trypan blue to quench 
extracellular fluorescence. To observe the localization of the cargo, cell fluorescence was 
analyzed using a Leica SP5 AOBS confocal laser scanning microscope using the 405 nm UV 
diode (for Hoechst staining), the 488 nm argon laser line (for FITC and Atto 488 staining), the 
543 nm HeNe laser line (for r-phycoerythrin and LysoTrackerRed staining) and the 633 HeNe 
laser line (for Alexa Fluor 647 staining). For emission detection, an appropriate spectral filter 
was used for each channel. 
  
6 
 
3. RESULTS AND DISCUSSION 
1. We synthesized a lead molecule (peptide WYKYW) and measured its interaction with 
different gangliosides (GM1, asialo-GM1, GM3). We showed that the sequence had high 
affinity (KD = 23.8 nM) and was specific towards ganglioside GM1. We showed that 
truncating the ganglioside GM1 resulted in decreased or completely abolished binding. 
 
2. We found that fluorescent tagging in proximity of the peptide tag was detrimental to the 
ganglioside binding. We introduced and synthesized two linkers to lengthen the tag: a PEG-
based one and a cell penetrating peptide (penetratin). We showed that both constructs 
retained high affinity towards ganglioside GM1. 
 
3. We used a medicinal chemistry approach to set up a structure–activity relationship between 
the amino acids of the sequence and their binding efficiency. We demonstrated that every 
amino acid and their configuration was important in the binding. We identified several 
sequence analogues constructed with backbone homologation, which had comparable 
affinity with the parent sequence (Table 1).  
Table 1. Binding affinities (KD) of the first binding-step in nM of the original pentapeptide 
substituted in various manners. The binding stoichiometry (n1) was 0.5 in all cases. 
 NW Y K Y WC 
original 23.8 
Ala-scan not fittable 5755 10467 1694 1060 
-scan 4.3 60 332 40 86 
D-scan 881 892 4523 3243 3926 
 
4. We revealed the importance of the membrane components in the binding. We measured 
both the tryptophan insertion into the membrane and the decreased aromatic face-to-edge 
interactions during the binding. 
 
5. We showed that the peptide tag was capable of triggering endocytosis at submicromolar 
concentrations of a 63 kDa protein, while avoiding the lysosomal pathways (Figure 1, 2a). 
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Figure 1. Internalization of the constructs at different concentrations by HeLa cells after 6 
hours as determined by live confocal laser scanning microscopy. FITC-labeled NeutrAvidin 
is shown in green, Hoechst 33342-stained nuclei are shown in cyan, and LysoTracker Red-
stained lysosomes are shown in magenta. 
6. We proved that the translocation was energy dependent, and that the process could be 
blocked with methyl--cyclodextrin, which showed that the endocytosis was lipid raft-
mediated (Figure 2b). 
 
Figure 2. (a) Internalization of the constructs at 1 M by HeLa cells after 1 hour as 
determined by flow cytometry. (b) Influence of endocytosis inhibitors on cellular uptake. 
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7. We demonstrated that the internalization was in correlation with the ganglioside GM1 
content of the cells. 
 
8. We carried out an in vivo titration with galectin-1, which could decrease the uptake of our 
complex to the base level displayed by our linker alone, strengthening the biomimetic 
behavior of our carrier. We confirmed this finding by observing co-localization of our 
complex and cholera toxin B subunit. 
 
9. We showed that the WYKYW-tagged sequence could efficiently internalize antibody 
complexes (ca. 580 kDa) into human cells at low nanomolar concentrations. We observed 
a diffuse fluorescence throughout the cytoplasm, which we confirmed with artificial 
intelligence aided quantitative analysis (Figure 3). 
 
Figure 3. (a) Schematic representation of the bottom-up designed modular carrier–hub–
antibody cargo–secondary antibody–r-phycoerythrin construct. (b) Artificial intelligence-aided 
quantitative analysis of the live CLSM images. HeLa cells were incubated for 6 hours with 
various concentrations of the IgG complex. (c) Delivery of the IgG complex into HeLa cells at 
various concentrations after 3 hours. R-phycoerythrin-conjugated secondary antibody is 
indicated in magenta; green staining defines cell membranes (WGA-FITC). Nuclei are 
indicated in cyan. Control cells were treated with r-phycoerythrin-labeled secondary antibody 
at 160 nM for 3 hours. 
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10. We verified that the molecular recognition between the primary and the secondary 
antibodies is functional. We showed that the delivered primary antibody is structurally 
intact. 
 
11. We showed that substituted sequences could internalize the IgG complex. We demonstrated 
that weaker binder sequences could be sufficient when increasing the avidity of the 
construct. We showed that decreasing the tryptophan content of the peptide tag was 
beneficial to the uptake of the construct. 
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